TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22945731

Group type: EXPERIMENTAL
Intervention: Irrigation with a hydroalcoholic solution of propolis extract twice a week for 2 weeks (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Irrigation with a placebo twice a week for 2 weeks (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No additional treatment (group C)
Number of subjects: 20
Study: 20490472

Group type: EXPERIMENTAL
Intervention: Blonanserin 2 mg oral dose, administered under different conditions: fasting, 30 min before meal, 30 min after meal, 2 h after meal, 4 h after meal.
Number of subjects: 0
Study: 18323713

Group type: EXPERIMENTAL
Intervention: Sun-style 24 forms of Tai Chi exercise for 60 min, 2 times per week for 12 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sun-style 24 forms of Tai Chi exercise
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 15785958

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 mug
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 20
Study: 12131653

Group type: EXPERIMENTAL
Intervention: Study group (direct contact)
Number of subjects: 2025

Group type: COMPARATOR
Intervention: Standard group (invitation letter)
Number of subjects: 2025
Study: 7559202

Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg
Number of subjects: 0
Study: 2783493

Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (TENS) for 30 minutes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 21
Study: 1092151

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (Ho‐Ku, LI4; Nei‐Kuan, EH‐6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Needling of arbitrarily chosen points
Number of subjects: 12
Study: 31373374

Group type: EXPERIMENTAL
Intervention: FFR + CSB
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: RFR + CSB
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: NFR + CSB
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: FFR + LNS
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: FFR + MNP
Number of subjects: 3535

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3535
Study: 28967627

Group type: EXPERIMENTAL
Intervention: Agar‐35 tea (n=6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo tea (n=8)
Number of subjects: 14
Study: 26334929

Group type: EXPERIMENTAL
Intervention: STRIDE lifestyle intervention (weekly group meetings for 6 months, then monthly for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STRIDE lifestyle intervention
Number of subjects: 0
Study: 23492960

Group type: EXPERIMENTAL
Intervention: Prebifurcation (PB) technique
Number of subjects: 68

Group type: COMPARATOR
Intervention: Bifurcation (B) technique
Number of subjects: 68
Study: 21198745

Group type: EXPERIMENTAL
Intervention: Group B (patients on dopamine agonist therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group A (control subjects)
Number of subjects: 40
Study: 19101780

Group type: EXPERIMENTAL
Intervention: Olmesartan (RAS inhibitor)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Antihypertensive drugs without RAS inhibitors
Number of subjects: 462
Study: 17876013

Group type: EXPERIMENTAL
Intervention: Cetuximab, bevacizumab, and irinotecan (CBI)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cetuximab and bevacizumab alone (CB)
Number of subjects: 83
Study: 15237752

Group type: EXPERIMENTAL
Intervention: Perturbed treadmill training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ordinary treadmill training
Number of subjects: 29
Study: 11237807

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 9934233

Group type: EXPERIMENTAL
Intervention: Mannitol and complementary antimicrobial therapeutics
Number of subjects: 20
Study: 7823116

Group type: EXPERIMENTAL
Intervention: Pointing task (reproduction by pointing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual reproduction (using two visual stimuli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both conditions (pointing and visual reproduction)
Number of subjects: 0
Study: 3370020

Group type: EXPERIMENTAL
Intervention: 9-week program of submaximal aerobic exercise three times weekly
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 55
Study: 331853

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31366395

Group type: EXPERIMENTAL
Intervention: Online home-based cognitive training (13 games focusing on executive functions, attention, and processing speed)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Active control (3 games to keep participants cognitively engaged without training)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Online home-based cognitive training
Number of subjects: 140

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 140
Study: 25084971

Group type: EXPERIMENTAL
Intervention: Antibiotic group (first-line antibiotics for 3 days)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No Antibiotic group
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study: 22345687

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg initially, increasing to 4 mg after 8 weeks if necessary)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 and 4 mg)
Number of subjects: 545
Study: 22157744

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interfascial injection of 5 mL of lidocaine 2%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nerve stimulation-assisted technique with 5 mL of lidocaine 2%
Number of subjects: 50
Study: 20501476

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered pre-sheath (before catheterization laboratory arrival)
Number of subjects: 5707

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered in-lab (after catheterization laboratory arrival)
Number of subjects: 5707
Study: 17711924

Group type: EXPERIMENTAL
Intervention: Oral estrogen (17beta-estradiol) at doses of 0.5, 1, and 2 mg for 2 weeks each
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (TD) at doses of 0.025, 0.0375, and 0.05 mg for 2 weeks each
Number of subjects: 11
Study: 16334438

Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mg kg-1 h-1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 7
Study: 11728834

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study: 9620107

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study: 8131535

Group type: EXPERIMENTAL
Intervention: Breathing and coughing exercises with physiotherapist supervision (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Breathing and coughing exercises with more frequent physiotherapist supervision (Group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No preoperative or postoperative chest physiotherapy (Group 1)
Number of subjects: 120
Study: 2478015

Group type: EXPERIMENTAL
Intervention: ATIII/heparin regimen (1,500 units preoperatively and 1,000 units daily for five days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ATIII (same dose as hip replacement)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ATIII (twice the dose used for hip replacement)
Number of subjects: 31

Group type: COMPARATOR
Intervention: ATIII/heparin, warfarin, or dextran
Number of subjects: 31
Study: 1266558

Group type: EXPERIMENTAL
Intervention: DHB 0.2 mg/kg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pentobarbital 2 mg/kg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Halothane with pentobarbital 2 mg/kg
Number of subjects: 84
Study: 31035902

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 793

Group type: COMPARATOR
Intervention: Control (nonstatin treatment)
Number of subjects: 793
Study: 26711466

Group type: EXPERIMENTAL
Intervention: Mouthwash and a moisturizing gel (M + m)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mouthwash (M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water and a moisturizing gel (W + m)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 60
Study: 27099884

Group type: EXPERIMENTAL
Intervention: Ongoing GDMT plus carotid baroreflex activation therapy (BAT) for 6 months
Number of subjects: 146

Group type: COMPARATOR
Intervention: Ongoing GDMT alone for 6 months
Number of subjects: 146
Study: 23484763

Group type: EXPERIMENTAL
Intervention: Bepotastine besilate ophthalmic solution (BBOS) 1.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22379790

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping plus cupping
Number of subjects: 60

Group type: COMPARATOR
Intervention: He-Ne laser irradiation
Number of subjects: 60
Study: 19663092

Group type: EXPERIMENTAL
Intervention: Suspended moxibustion at Baihui (GV 20)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Estazolam (oral administration)
Number of subjects: 75
Study: 16988594

Group type: EXPERIMENTAL
Intervention: 5 mg Delta‐9‐THC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20 mg CBD
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 40 mg CBD
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 12949690

Group type: EXPERIMENTAL
Intervention: Proproten-100
Number of subjects: 0
Study: 11035338

Group type: EXPERIMENTAL
Intervention: Standard corticosteroid dosage regimen for promotion of fetal lung maturation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid regimen of >24 mg/d (10 mg dexamethasone IV every 6 hours for 2 doses followed by 6 mg IV every 6 hours for 2 to 4 doses)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No corticosteroids
Number of subjects: 37
Study: 9447770

Group type: EXPERIMENTAL
Intervention: Colgate 0-6 gel (400 ppm F)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Colgate Great Regular Flavour (GRF) (1450 ppm F)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Smear instruction
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pea-sized instruction
Number of subjects: 53
Study: 8417421

Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 144
Study: 3087861

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg
Number of subjects: 172

Group type: COMPARATOR
Intervention: Bicillin (procaine penicillin)
Number of subjects: 172
Study: 29146890

Group type: EXPERIMENTAL
Intervention: Green tea ointment 3%
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 372
Study: 27107670

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Benzodiazepine dosage reduction
Number of subjects: 78
Study: 26862634

Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isonitrogenous arm (control)
Number of subjects: 60
Study: 22908105

Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) treatment (voucher for lower-poverty neighborhoods)
Number of subjects: 2829

Group type: COMPARATOR
Intervention: Control group (no voucher)
Number of subjects: 2829
Study: 20100810

Group type: EXPERIMENTAL
Intervention: Weight management intervention with smoking cessation
Number of subjects: 284

Group type: COMPARATOR
Intervention: Tests that do not require the MCAR assumption
Number of subjects: 284
Study: 17882375

Group type: EXPERIMENTAL
Intervention: Stentless mitral valve (SMV)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Mitral valve repair (MV-rep)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional mitral valve replacement (MVR)
Number of subjects: 155
Study: 16293412

Group type: EXPERIMENTAL
Intervention: Dydrogesterone 40 mg stat dose followed by 10 mg twice a day for one week
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 154
Study: 12199727

Group type: EXPERIMENTAL
Intervention: Short-echo-time proton magnetic resonance spectroscopy imaging (MRSI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 10403975

Group type: EXPERIMENTAL
Intervention: Evidence-based nursing practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 7502999

Group type: EXPERIMENTAL
Intervention: Plasma selenium levels in cases with MI (mean 114.4 ± 15.1 ng/g)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Plasma selenium levels in controls (mean 113.2 ± 15.7 ng/g)
Number of subjects: 502
Study: 2102136

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg b.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketanserin 20 mg b.i.d. and 40 mg b.i.d.
Number of subjects: 12
Study: 86158

Group type: EXPERIMENTAL
Intervention: Topical 10% adenine arabinoside 5'-monophosphate
Number of subjects: 233
Study: 30668853

Group type: COMPARATOR
Intervention: 6L:18D
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 8L:16D
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 10L:14D
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: ≥10 h photoperiods
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: ≥8‐h photoperiods
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: ≥12 h
Number of subjects: 480
Study: 27582421

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 26153671

Group type: EXPERIMENTAL
Intervention: Infant-daily nevirapine
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral (zidovudine, lamivudine and either nevirapine, nelfinavir or lopinavir-ritonavir)
Number of subjects: 2369

Group type: COMPARATOR
Intervention: No further antiretroviral prophylaxis (control arm)
Number of subjects: 2369
Study: 23838656

Group type: EXPERIMENTAL
Intervention: Concentric dilated LVH
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Eccentric dilated LVH
Number of subjects: 939

Group type: COMPARATOR
Intervention: Eccentric nondilated LVH
Number of subjects: 939
Study: 21249332

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 2127
Study: 19695526

Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (30 minutes) followed by stretching exercises (2 minutes); 3 treatments per week for 2 weeks.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Stretching exercises after ultrasound therapy (30 minutes); 3 treatments per week for 2 weeks.
Number of subjects: 15
Study: 15650862

Group type: EXPERIMENTAL
Intervention: aepEX
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: bispectral index
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SEF95%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: aepEX, bispectral index, SEF95%
Number of subjects: 40
Study: 12764910

Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SMI) plus conventional treatment of western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 60
Study: 10496553

Group type: EXPERIMENTAL
Intervention: HIV-positive patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients with acquired immunodeficiency syndrome
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (seronegative patients)
Number of subjects: 48
Study: 8983893

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 163

Group type: COMPARATOR
Intervention: Ceftibuten
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 163
Study: 1917174

Group type: EXPERIMENTAL
Intervention: Continuous treatment (two 10 mg/24 hour patches twice daily, at 8 a.m. and 8 p.m.)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (two 10 mg/24 hour patches at 8 a.m. and two placebo patches at 8 p.m.)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (two placebo patches twice daily, at 8 a.m. and 8 p.m.)
Number of subjects: 88
Study: 6461943

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31169226

Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scan
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Negative PET-CT at the first follow-up
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Baseline maximum standardized uptake value (SUVmax)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall accuracy of PET-CT
Number of subjects: 59
Study: 27730252

Group type: EXPERIMENTAL
Intervention: Video-assisted feedback
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral feedback
Number of subjects: 100
Study: 26399403

Group type: EXPERIMENTAL
Intervention: Asleep systolic ABP mean
Number of subjects: 2656

Group type: COMPARATOR
Intervention: Daytime clinic BP and awake or 48 h ABP mean
Number of subjects: 2656
Study: 24393491

Group type: EXPERIMENTAL
Intervention: Condition 1: Basic feedback regarding clients' symptoms and quality of life
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Condition 2: Extended feedback with obstacles and practical suggestions
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Condition 3: Feedback discussed with a colleague using a standardized format
Number of subjects: 432
Study: 21987650

Group type: EXPERIMENTAL
Intervention: Sphenoidal process length measurement during septal surgery
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Deviation angle measurement at the ostiomeatal unit
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Deviation angle measurement at the nasal valve area
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Length of ANS-PPE measurement
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Length of ANS-CS measurement
Number of subjects: 136
Study: 19664956

Group type: COMPARATOR
Intervention: Standard topical 4% lidocaine cream and injection of [(99m)Tc]Tc‐sulfur colloid (n=35)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical placebo cream and injection of Tc‐sulfur colloid containing sodium bicarbonate (n=35)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical placebo cream and injection of Tc‐sulfur colloid containing 1% lidocaine (n=35)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical placebo cream and injection of Tc‐sulfur colloid containing sodium bicarbonate and 1% lidocaine (n=35)
Number of subjects: 140
Study: 17211264

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Medoff Sliding Plate (MSP)
Number of subjects: 203
Study: 16398423

Group type: EXPERIMENTAL
Intervention: Xiaoshui Decoction (XSD) combined with chemotherapy (DDP via abdominal infusion)
Number of subjects: 61

Group type: COMPARATOR
Intervention: DDP infusion alone (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: XSD in experimental study (mice models)
Number of subjects: 61

Group type: COMPARATOR
Intervention: DDP in experimental study (control group for mice)
Number of subjects: 61
Study: 12526189

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulators (SERMs)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 9690723

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg t.d.s.)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Tripotassium dicitrato bismuthate (TDB) (120 mg q.d.s.)
Number of subjects: 86
Study: 8620674

Group type: EXPERIMENTAL
Intervention: Zileuton 800mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2703967

Group type: EXPERIMENTAL
Intervention: Methocarbamol 2.25, 4.5, and 9 g
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lorazepam 1, 2, and 4 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 579342

Group type: EXPERIMENTAL
Intervention: Tolamolol
Number of subjects: 15
Study: 30590612

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive intervention program for PE teachers over 3 months
Number of subjects: 681

Group type: COMPARATOR
Intervention: Control group (teachers not receiving the autonomy-supportive intervention)
Number of subjects: 681
Study: 30773586

Group type: COMPARATOR
Intervention: Canola oil diet (17.5% MUFAs, 9.2% PUFAs, 6.6% SFAs)
Number of subjects: 119

Group type: COMPARATOR
Intervention: High-oleic acid canola oil (HOCO) diet (19.1% MUFAs, 7.0% PUFAs, 6.4% SFAs)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control oil blend (10.5% MUFAs, 10.0% PUFAs, 12.3% SFAs)
Number of subjects: 119
Study: 26559708

Group type: EXPERIMENTAL
Intervention: Children's Power Play! Campaign
Number of subjects: 3463

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3463
Study: 25929710

Group type: EXPERIMENTAL
Intervention: Invisalign® aligners
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fixed brackets
Number of subjects: 50
Study: 22982605

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (20mg-oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: haloperidol (2mg-oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 21888655

Group type: COMPARATOR
Intervention: Methylene blue alone (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined technique (sulfur colloid labeled with 99 m Technetium, gamma-probe guided surgery, and methylene blue) (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All patients (combined data)
Number of subjects: 90